Solution
Identifying patients who are truly at risk for reactions to PEG-containing products has remained a persistent challenge in allergy diagnostics. Conventional approaches, including ELISA and skin prick testing, may lack the sensitivity, specificity, or reproducibility required to reliably detect anti-PEG IgE, particularly when antibody levels are low or results fall near clinical decision thresholds. Consequently, clinicians may face significant uncertainty when evaluating patients with unexplained immediate hypersensitivity reactions or when assessing risk before administration of PEG-containing therapies.
The FocalTuning™ platform is designed to address this diagnostic gap. By integrating proprietary signal deconvolution with precision background-correction technologies, FocalTuning enables highly sensitive, specific, and accurate detection of anti-PEG IgE. This improved analytical performance helps distinguish true immunologic reactivity from nonspecific background interference, thereby increasing diagnostic confidence.
Unlike conventional assays that may fail to detect low-abundance or weakly reactive antibodies, FocalTuning is engineered to resolve subtle but clinically relevant IgE signals. By enabling earlier and more reliable identification of patients at elevated risk for PEG-mediated hypersensitivity, the platform has the potential to support safer clinical decision-making, improve patient stratification, and reduce preventable adverse reactions associated with PEG-containing drugs and medical products.
Human PEG IgE Detection Kit
